Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) Sees Significant Increase in Short Interest

Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS – Get Rating) saw a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 113,000 shares, an increase of 32.0% from the March 15th total of 85,600 shares. Based on an average trading volume of 1,440,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 1.2% of the shares of the company are short sold.

NASDAQ:ARDS opened at $1.44 on Monday. Aridis Pharmaceuticals has a 12 month low of $1.13 and a 12 month high of $7.72. The stock has a 50 day moving average of $1.84 and a two-hundred day moving average of $2.30. The firm has a market cap of $20.24 million, a P/E ratio of -0.35 and a beta of 0.24.

Aridis Pharmaceuticals (NASDAQ:ARDS – Get Rating) last posted its quarterly earnings data on Friday, April 1st. The company reported ($0.92) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by ($0.51). Analysts anticipate that Aridis Pharmaceuticals will post -1.79 earnings per share for the current year.

Large investors have recently bought and sold shares of the business. Virtu Financial LLC purchased a new stake in Aridis Pharmaceuticals during the 4th quarter worth approximately $28,000. Citadel Advisors LLC purchased a new stake in shares of Aridis Pharmaceuticals in the fourth quarter valued at approximately $34,000. Commonwealth Equity Services LLC purchased a new stake in shares of Aridis Pharmaceuticals in the fourth quarter valued at approximately $47,000. Wealth Architects LLC purchased a new stake in shares of Aridis Pharmaceuticals in the third quarter valued at approximately $52,000. Finally, Minot Wealth Management LLC purchased a new stake in shares of Aridis Pharmaceuticals in the first quarter valued at approximately $88,000. Institutional investors own 14.21% of the company’s stock.

Separately, Zacks Investment Research cut Aridis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, April 7th.

About Aridis Pharmaceuticals (Get Rating)

Aridis Pharmaceuticals, Inc, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S.

Further Reading